Market Place
Sourcing Support
FDA Grants RMAT for enGene’s Detalimogene for Bladder Cancer
25 Jun 2025 //
BUSINESSWIRE
enGene Reports Q2 2025 Financial Results and Business Update
12 Jun 2025 //
BUSINESSWIRE
enGene Announces the Resignation of its Chief Medical Officer
04 Jun 2025 //
BUSINESSWIRE
enGene to Present at the Jefferies Global Healthcare Conference
29 May 2025 //
BUSINESSWIRE
enGene Names Amy Pott as Chief Global Commercialization Officer
28 May 2025 //
BUSINESSWIRE
enGene to Participate in Upcoming Investor Conferences
29 Apr 2025 //
BUSINESSWIRE
enGene to Participate in Upcoming Investor Conferences
28 Apr 2025 //
BUSINESSWIRE
enGene to Present at Stifel 2025 Oncology Forum
01 Apr 2025 //
BUSINESSWIRE
enGene Reports Q1 2025 Financial Results and Business Update
10 Mar 2025 //
BUSINESSWIRE
enGene To Join Leerink Partners Global Healthcare Conference
04 Mar 2025 //
BUSINESSWIRE
enGene to Present at Oppenheimer 35th Annual Healthcare Conference
04 Feb 2025 //
BUSINESSWIRE
enGene Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
31 Jan 2025 //
BUSINESSWIRE
enGene To Present Three Posters On Detalimogene Voraplasmid
30 Jan 2025 //
BUSINESSWIRE
enGene Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
30 Dec 2024 //
BUSINESSWIRE
enGene Reports Full-Year 2024 Results & Business Update
19 Dec 2024 //
BUSINESSWIRE
enGene to Participate in Upcoming Investor Conferences
25 Nov 2024 //
BUSINESSWIRE
enGene to Participate in Guggenheim Health Innovation Conference
05 Nov 2024 //
BUSINESSWIRE
enGene Announces $60 Million Private Placement Financing
25 Oct 2024 //
BUSINESSWIRE
enGene Reports Inducement Grant Under NASDAQ Rule
22 Oct 2024 //
BUSINESSWIRE
enGene Appoints Joan Connolly As CTO And Anthony Cheung As CSO
21 Oct 2024 //
BUSINESSWIRE
Detalimogene Shows 71% Complete Response In LEGEND
26 Sep 2024 //
BUSINESSWIRE
enGene Reports Q3 2024 Results And Business Update
10 Sep 2024 //
BUSINESSWIRE
enGene to Participate in Upcoming Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
24 Jul 2024 //
BUSINESSWIRE
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
24 Jul 2024 //
BUSINESSWIRE
EnGene Reports Q2 2024 Results Provides Business Update
14 Jun 2024 //
BUSINESSWIRE
enGene drops cystic fibrosis program to focus on bladder cancer
14 Jun 2024 //
FIERCE BIOTECH
enGene Elects Paul Hastings, Wouter Joustra To Board Of Directors
15 May 2024 //
BUSINESSWIRE
enGene To Present LEGEND Phase 1/2 Bladder Cancer Data At AUA
02 May 2024 //
PR NEWSWIRE
enGene Hires Dr. Pruthi As Urologic Oncology SVP
09 Apr 2024 //
PR NEWSWIRE
enGene Reports First Quarter 2024 Financial Results & Recent Corporate Progress
11 Mar 2024 //
PR NEWSWIRE
enGene To Present at the Leerink Partners Global Biopharma Conference
05 Mar 2024 //
PR NEWSWIRE
enGene Announces Leadership Succession Plan
14 Feb 2024 //
PR NEWSWIRE
enGene Announces Oversubscribed $200 Million Private Placement Financing
14 Feb 2024 //
PR NEWSWIRE
enGene Announces Expanded $50 Million Debt Facility with Hercules Capital
22 Dec 2023 //
PR NEWSWIRE
enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors
19 Dec 2023 //
PR NEWSWIRE
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
01 Nov 2023 //
PR NEWSWIRE
enGene starts trading on Nasdaq after completing Forbion SPAC deal
01 Nov 2023 //
ENDPTS
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
07 Sep 2023 //
BIOSPACE
SPAC in business: Gene therapy biotech takes blank-check route
17 May 2023 //
FIERCE BIOTECH
enGene announces presentation containing Phase 1 clinical trial data at ASCO
14 Feb 2023 //
PR NEWSWIRE
enGene Appoints Alex Nichols, PhD as President and Chief Operating Officer
02 Feb 2023 //
PR NEWSWIRE
enGene Appoints James C. Sullivan, PhD as Chief Scientific Officer
17 Mar 2022 //
PRNEWSWIRE
enGene Shows Positive Preliminary Phase 1/2 Data with EG-70 in Bladder Cancer
08 Feb 2022 //
PRNEWSWIRE
Immunovia to Host a Key Opinion Leader Event on the Clinical Use of IMMray™
27 May 2021 //
PRNEWSWIRE
enGene Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle
27 May 2021 //
PRNEWSWIRE
enGene Receives Fast Track Designation for EG-70
04 Dec 2020 //
PRNEWSWIRE
